Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2002
04/16/2002US6372786 Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
04/16/2002US6372784 Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
04/16/2002US6372783 Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
04/16/2002US6372779 Anthracene derivatives with carbamoyl groups, amido groups, urea groups and sulfonamide groups
04/16/2002US6372778 Sulfonamide inhibitors of aspartyl protease
04/16/2002US6372777 Cyclic AMP-specific phosphodiesterase inhibitors
04/16/2002US6372776 Crystalline(−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate
04/16/2002US6372774 Derivatives of N-phenylpyrazoles
04/16/2002US6372773 Treatment of inflammation, arthritis with urea or thiourea heterocycles
04/16/2002US6372772 Inhibitors of redox signaling and methods of using same
04/16/2002US6372768 2-aminopyridines containing fused ring substituents
04/16/2002US6372767 Benzanilides as potassium channel openers
04/16/2002US6372763 Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
04/16/2002US6372762 Heterocyclic compounds for nervous system disorders
04/16/2002US6372760 Stabilized composition comprising antidementia medicament
04/16/2002US6372759 Antithrombotic agents
04/16/2002US6372758 Sulfamato hydroxamic acid metalloprotease inhibitor
04/16/2002US6372757 Phenylurea and phenylthio urea derivatives
04/16/2002US6372756 Narcotics or analgesics
04/16/2002US6372755 Includes at least one of a water soluble antioxidant, a fat soluble antioxidant, a synergist, a sugar and a surfactant
04/16/2002US6372754 Drugs for treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpic neuralgia.
04/16/2002US6372753 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
04/16/2002US6372751 Drugs with benzene and pyrimidine rings
04/16/2002US6372746 Derivatives of acyl-piperazinyl-pyrimidines, preparation thereof and application as medicaments
04/16/2002US6372745 2,3,4,4A-tetrahydro-1H-pyrazino[1,2-A]quinoxalin-5(6H)one derivatives
04/16/2002US6372744 β-sheet mimetics and methods relating to the use thereof
04/16/2002US6372743 Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
04/16/2002US6372742 Telomerase enzyme inhibitors and anticancer agents
04/16/2002US6372741 Use of CSAID™ compounds as inhibitors of angiogenesis
04/16/2002US6372740 2-aryl-8-oxodihydropurine derivative, process for the producing the same, medicinal compositions containing the same, and intermediates thereof
04/16/2002US6372738 Cytotoxic agents comprising taxanes and their therapeutic use
04/16/2002US6372735 Antihistamines
04/16/2002US6372734 Crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
04/16/2002US6372732 Treatment of autoimmune disorders with steroids
04/16/2002US6372731 Vitamin D derivatives with C-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments
04/16/2002US6372730 2-decarboxy-2-phosphinico Prostaglandin F analogs
04/16/2002US6372729 Treatment of viral diseases such as aids
04/16/2002US6372728 Formulation for treatment of osteoporosis
04/16/2002US6372727 Metalloporphyrin treatment of neurologic disease
04/16/2002US6372726 Methods of cancer treatment using NAALADase inhibitors
04/16/2002US6372724 Modulation of human mast cell activation
04/16/2002US6372723 Administering selective adenosine a2a receptor agonist and/or antagonist; occlusion removal; surgery; reroute blood flowthrough bypass graft
04/16/2002US6372719 ανβ3 integrin antagonists in combination with chemotherapeutic agents
04/16/2002US6372490 Nucleic acid encoding the MDM interacting protein
04/16/2002US6372487 Polynucleotides encoding peptide release factor, prfC (RF-3), a GTP-binding protein
04/16/2002US6372473 Tissue plasminogen activator-like protease
04/16/2002US6372462 Cultivating a fungi of the basidiomycetes in a submerged culture on nutrient media, isolating the biomass of edible mushrooms from the culture broth, and drying at a range of 40-45 degrees celsius
04/16/2002US6372433 Antisense modulation of inhibitor of DNA binding-1 expression
04/16/2002US6372431 Mammalian toxicological response markers
04/16/2002US6372267 Cocoa solids prepared by heating, pressing, recovering partially defatted cocoa solids which contain cocoa polyphenols including cocoa procyanidins
04/16/2002US6372266 Medicinal composition for treating dysmenorrhea and endometriosis industrial use
04/16/2002US6372264 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
04/16/2002US6372258 Methods of spray-drying a drug and a hydrophobic amino acid
04/16/2002US6372255 Tablet for instant and prolonged release of one or more active substances
04/16/2002US6372253 Rapidly disintegrating methylcellulose tablets
04/16/2002US6372252 Containing quantity of medicine in immediate release layer and second portion in release-delay matrix of hydrophilic polymer and water insoluble polymer
04/16/2002US6372251 Bioavailability
04/16/2002US6372250 Non-invasive gene targeting to the brain
04/16/2002US6372243 Perfluoroalkane or fluorohydrocarbons deoxygenated which prevents their damage to the retina or intraocular structures; use such as treating ischemic retinal disorders
04/16/2002US6372231 Gelatinous composition
04/16/2002US6372229 Curing water soluble proteinaceous material and di- or polyaldehyde
04/16/2002US6372202 Cosmetic composition, in particular a make-up composition, comprising a pigment derived from pyrrolopyrrole
04/16/2002US6372199 Use of unsymmetrically substituted triazine derivatives in cosmetic or dermatological preparations for maintaining the urocanic acid status of the skin
04/16/2002US6372198 Containing water soluble calcium salt, water soluble phosphate salt and ubiquinone
04/16/2002US6372197 Methods and compositions using norastemizole in combination with leukotriene inhibitors
04/16/2002US6372196 Hemostatically active aerosol composition of polyanhydroglucoronic acids and its salts
04/16/2002US6371975 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
04/16/2002CA2355334A1 Pharmaceutical preparations and methods for inhibiting tumors
04/16/2002CA2266629C Taste-masked microcapsule compositions and methods of manufacture
04/16/2002CA2260413C Terpenoid lactone compounds and their production process
04/16/2002CA2218552C Benzimidazole compounds and their use as modulators of the gabaa receptor complex
04/16/2002CA2217601C Benzimidazole compounds and their use as modulators of the gabaa receptor complex
04/16/2002CA2186037C New pharmaceutical formulation and process
04/16/2002CA2143252C Benzodioxanes derivatives; process for preparing the same and pharmaceutical compositions containing them
04/16/2002CA2114593C Indole, indazole and benzisoxazole derivatives, process for their preparation and pharmaceutical compositions containing them
04/16/2002CA2103556C Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents, and processes for their preparation
04/16/2002CA2088980C Pro-drugs for cck antagonists
04/16/2002CA2087414C Arylcycloalkyl derivatives their production and their use
04/16/2002CA2076948C Isatineoxime derivatives, their preparation and use
04/16/2002CA2061665C Treatment of lower urinary tract disorders
04/16/2002CA2056503C Stable, solid acetylperoxyborate compounds
04/16/2002CA2054629C Pharmaceutical composition
04/16/2002CA2046607C Inhibiting transformation of cells having elevated purine metabolic enzyme activity
04/16/2002CA2009690C Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
04/15/2002WO2002030514A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
04/15/2002CA2421622A1 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
04/13/2002CA2321189A1 Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof
04/11/2002WO2002029418A1 Selective anxiolytic therapeutic agents
04/11/2002WO2002029086A2 Nucleic acid sequences differentially expressed in cancer tissue
04/11/2002WO2002029044A2 Modulation of the transcription of pro-inflammatory gene products
04/11/2002WO2002029035A2 Method to alter sugar moieties
04/11/2002WO2002029014A2 Stem cell differentiation-inducing promoter
04/11/2002WO2002028906A2 Regulation of human sphingosine kinase-like protein
04/11/2002WO2002028897A2 Human g-protein coupled receptor and uses thereof
04/11/2002WO2002028881A1 Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
04/11/2002WO2002028880A2 Compounds useful for treating hypertriglyceridemia
04/11/2002WO2002028874A2 Tumor proliferation inhibitors
04/11/2002WO2002028872A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
04/11/2002WO2002028871A1 Platinum complexes as antitumor agents
04/11/2002WO2002028868A1 Thiazine derivatives